Staar Surgical Co (STAA) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jul 03 2026 to Jun 27 2025 - CSIMarket
Staar Surgical Co's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Staar Surgical Co's ROI in the second quarter of 2026? Staar Surgical Co achieved a return on average invested assets (ROI) of 0.98 % in its second quarter of 2026, this is above STAA's average return on investment of -3.27%. Staar Surgical Co invested over the 12 months ending in its second quarter of 2026 $392 million
ROI has improved compared to -5.44% in the first quarter of 2026, due to net income growth.
Within the Healthcare sector 120 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2694 to 2896.
In the illustrious domain of advanced ocular innovations, STAAR Surgical Company, a venerable developer, manufacturer, and purveyor of the renowned EVO family of Implantable Collamer Lenses (EVO ICLâ„¢), is poised to augment its commitment to the medical fraternity. From its esteemed headquarters nestled within the picturesque confines of Lake Forest, California, adjacent to the illustrious John Wayne Airport, the company proudly heralds the expansion of the STAAR Surgical Experience Center.This newly inaugurated establishment serves as a beacon of enlightenment, providing an expansive and comprehensive milieu for hands-on training and education in the nuanced application of its celebrated vision-corrective technologies. The influx of demand for advancements in ophthalmological equipment necessitated this expansion; a movement both laudable and requisite as more surgeons seek to enhance the quality of their practice with innovation at their fingertips.
STAAR Surgical Attracts Top Industry Executives Arthur Butcher and Wei Jiang to its Board of Directors Lake Forest, Calif. - STAAR Surgical Company (NASDAQ: STAA), a renowned leader in the development, manufacturing, and marketing of the innovative EVO family of Implantable Collamer Lenses (ICL) for the correction of myopia, astigmatism, and presbyopia, proudly announces the appointment of two distinguished industry leaders, Arthur Butcher and Wei Jiang, to its esteemed Board of Directors. Arthur Butcher, currently serving as the Executive Vice President and Group President of MedSurg and Asia Pacific for Boston Scientific, brings with him a wealth of knowledge, experience, and strategic insights into the global healthcare sphere. With his proven track record of driving growth and transformation within the medical device industry, Butcher s addition to STAAR Surgical s Board is expected to be a significant asset in expanding the company s global footprint.
STAAR Surgical Appoints Lilian Zhou to Its Board of Directors, Achieves Positive Return on Investment In a recent press release, STAAR Surgical Company has proudly announced the appointment of Lilian Zhou as a new member to its Board of Directors, effective from December 4, 2023. Lilian Zhou, an accomplished investment portfolio manager with experience at highly regarded Wall Street investment firms, brings valuable expertise to the industry-leading developer, manufacturer, and marketer of the EVO family of Implantable Collamer Lenses (ICL) for myopia, astigmatism, and presbyopia. This latest addition to STAAR Surgical s Board of Directors is expected to further enhance the company s strategic decisions and drive its growth in the ever-evolving healthcare market. With Zhou s extensive experience in investment management, STAAR Surgical can tap into a wealth of knowledge and potentially establish new partnerships and opportunities to expand its reach.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
